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Abstract
The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19
pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary
arterial hypertension, where pulmonary arterial hypertension-specific treatments are used. It is important to balance the ongoing
care and evaluation of pulmonary arterial hypertension patients with ‘‘exposure risk’’ to COVID-19 for patients coming to clinic or
the hospital. If there is a morbidity and mortality benefit from starting pulmonary arterial hypertension therapies, for example in a
patient with high-likelihood of pulmonary arterial hypertension, then it remains important to complete the thorough evaluation.
However, the COVID-19 outbreak may also represent a unique time when pulmonary hypertension experts have to weigh the
risks and benefits of the diagnostic work-up including potential exposure to COVID-19 versus initiating targeted pulmonary
arterial hypertension therapy in a select high-risk, high likelihood World Symposium Pulmonary Hypertension Group 1 pulmonary
arterial hypertension patients. This document will highlight some of the issues facing providers, patients, and the pulmonary arterial
hypertension community in real-time as the COVID-19 pandemic is evolving and is intended to share expected common clinical
scenarios and best clinical practices to help the community at-large.
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Introduction
The coronavirus disease of 2019 (COVID-19) pandemic
presents many unique challenges when caring for patients
with pulmonary hypertension (PH), particularly for those
patients with pulmonary arterial hypertension (PAH), and
chronic thromboembolic pulmonary hypertension (CTEPH).
This document will highlight some of the issues facing pro-
viders, patients, and the PAH community at-large in real-time
as the COVID-19 pandemic is evolving. Acknowledging up
front that there is a lack of formal guideline consensus and
scientific evidence to direct PAH providers and patients on
best practices for COVID-19-infected and COVID-affected
PAH patients currently, this document is intended to share
common clinical scenarios encountered and suggest best clin-
ical practices for caring for patients with PAH (Table 1). The
impetus for this manuscript was a recent discussion within
the Pulmonary Hypertension Association (PHA) and their
Scientific Leadership Council who expressed a need for guide-
lines from experts in the field. It should be noted that this
document is not meant to be all-inclusive nor to give specific
in-hospital management of a PAH patient with COVID-19,
as the evidence for such advice is currently lacking, but rather
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to assist in patient care and management to prevent hospital-
ization and improve clinical care during this pandemic.
A note on PH
While the focus of this communication is on patients with
PAH, the presence of PH, whether pre-existing or as a
direct result of the lung injury that occurs with COVID-19
infection, cardiomyopathy that may result from COVID-19
infection, or other comorbidity related to non-Group 1 PH
(Table 2), is likely to be a major contributor to the morbidity
and mortality associated with COVID-19 infection. As with
the approach to PAH patients, patients with PH must be
evaluated in the context of the severity of their illness.
Because there are no specific treatments for patients with
PH, specific management strategies for these patients will
not be addressed. CTEPH is in a unique position first,
because a curative treatment is available in the form of pul-
monary endarterectomy (PEA). However, in the absence of
decompensated right heart failure (RHF), how urgently sur-
gery should be performed is an issue that gets raised, espe-
cially when PEA is done best in a few select, specialized
centers. In this manuscript, the discussions around PAH
will also largely apply to CTEPH, with the acknowledgment
that it is an area of uncertainty as to when and whether
someone should go for PEA during the COVID-19 pan-
demic, with the anticipated increased needs for extracorpor-
eal membrane oxygenation (ECMO) and ventilators, plus the
exposure risk associated with being hospitalized at this time.
COVID-19 pandemic
The COVID-19 which first appeared in Wuhan, China, is
caused by severe acute respiratory syndrome coronavirus 2.
On 20 January 2020, the World Health Organization
declared the COVID-19 outbreak as an international
public health emergency, which was upgraded to a pandemic
on Wednesday, 11 March 2020.1 Those with underlying pul-
monary and cardiovascular disease (CVD) are at increased
risk for adverse outcomes from COVID-19.2 This is likely
due to the fact that the infection is associated with cardio-
vascular complications, including acute coronary syndrome,
cardiac arrest, myocarditis, cardiomyopathy, venous
thromboembolism, and acute respiratory distress syndrome
(ARDS) among others.3
Implications for PAH care
The COVID-19 pandemic has altered routine practice and
the acute management of PAH patients. Currently, the most
challenging aspect of ongoing care of PAH patients is
Table 1. Considerations for pulmonary hypertension programs
during COVID-19 pandemic.
Adopt a temporary visit (new and returning) schedule to balance
exposure risk with benefit of evaluation. Consider telemedicine
visits as an alternate, as long as patient accessibility is addressed.
Establish protocols for PAH work-up and evaluation to decrease the
risk of exposure or transmission of COVID-19. For example, con-
sider less frequent echocardiography and 6MWT testing on stable
patients and avoid pulmonary function or V/Q testing if possible.
Airway management and oxygenation is challenging in PAH with
respiratory failure. Best practice should be shared throughout the
PAH community regarding use of BiPAP/CPAP, intubation, ventila-
tors, and even home nitric oxide delivery systems.
Stratify need for right heart catheterization based on pre-test prob-
ability of group 1 PAH and risk profile of new or returning patients
who require augmentation of PAH therapy.
Follow NIH, FDA, Sponsor, and institutional guidance on limiting and/
or halting enrolment in PAH clinical trials.
PAH: pulmonary arterial hypertension; COVID-19: coronavirus disease of 2019;
6MWT: six-minute walk test; NIH: National Institutes of Health; FDA: Food and
Drug administration.





1.3 Drug- and toxin-induced PAH
1.4 PAH associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.5 PAH long-term responders to calcium channel blockers
1.6 PAH with overt features of venous/capillaries (PVOD/PCH)
involvement
1.7 Persistent PH of the newborn syndrome
2 PH due to left heart disease
2.1 PH due to heart failure with preserved LVEF
2.2 PH due to heart failure with reduced LVEF
2.3 Valvular heart disease
2.4 Congenital/acquired cardiovascular conditions leading to
post-capillary PH
3 PH due to lung diseases and/or hypoxia
3.1 Obstructive lung disease
3.2 Restrictive lung disease
3.3 Other lung disease with mixed restrictive/obstructive pattern
3.4 Hypoxia without lung disease
3.5 Developmental lung disorders
4 PH due to pulmonary artery obstructions
4.1 Chronic thromboembolic PH
4.2 Other pulmonary artery obstructions
5 PH with unclear and/or multifactorial mechanisms
5.1 Haematological disorders
5.2 Systemic and metabolic disorders
5.3 Others
5.4 Complex congenital heart disease
PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; PVOD:
pulmonary veno-occlusive disease; PCH: pulmonary capillary hemangiomatosis;
LVEF: left ventricular ejection fraction.
Source: reproduced with permission from Simonneau et al.32
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considering ‘‘exposure risk’’ for patients coming to the clinic
or hospital for follow-up and new appointments, including
routine laboratory tests. Some programs are able to perform
video visits for low-risk patients and to help determine if
the intermediate and high-risk patients as well as those
actively needing management require in-person evaluation.
Many PAH providers serve several roles, as pulmonologists,
cardiologists, pediatric specialists, intensivists, as well as
caregivers and parents. As the inpatient needs increase
during the COVID-19 pandemic, physicians within PAH
programs may be called to spend more time on inpatient
services further limiting their ability to be readily available
to their routine PAH patient care. Additionally, with pro-
viders spending time in isolation or caring for children, their
ability to care for PAH patients will be further challenged.
Finding means to streamline outpatient care during this time
and offload physicians by utilization of advanced practice
providers and nurses, telemedicine visits, as well as specialty
pharmacies can greatly improve touch points with patients
to prevent missing signs of worsening clinical and risk
status.
New patients
Clinic visits and evaluations
New referrals for PAH continue to require thorough evalu-
ation to carefully exclude Groups 2 and 3 PH before starting
PAH-specific therapies. This presents a challenge because
many healthcare settings have currently gone to emergency
status, where elective procedures, including clinic visits, pul-
monary function testing, echocardiography, CT scanning,
ventilation/perfusion (V/Q) scanning, and right heart cath-
eterization (RHC) are being deferred to facilitate staffing of
crucial services and to avoid inadvertent exposure.
Of note, since the COVID-19 pandemic, some institutions
have temporarily moved to computed tomography pulmon-
ary angiogram as first line for the evaluation of CTEPH
instead of V/Q scan or less commonly heart catheterization
with selective PA angiography. Other centers have elected to
temporarily eliminate the ventilation portion of the V/Q
study, due to the difficulty in disinfecting the ventilation sys-
tems.4 If lung perfusion images show no evidence of pulmon-
ary thromboembolism, then one can rule out CTEPH and
avoid more invasive imaging in the catheterization lab.
If there is a morbidity and/or mortality benefit from
starting PAH therapies, particularly for a patient with
high likelihood of having PAH, it is important to complete
a thorough evaluation, including measurement of invasive
hemodynamics, as per diagnostic guidelines.5 However,
the COVID-19 outbreak represents a unique time period
where PH experts may have to weigh the risks of COVID-
19 exposure during elective procedures such as RHC, and
the benefits of this evaluation to facilitate targeted PAH
therapies. In this setting, PAH-providers may be able to
work with companies for insurance provisional approval,
during urgent or emergent initiation of therapy. The value
of performing an elective RHC in patients with a high like-
lihood of Group 2 or Group 3 PH, where the benefit of PAH
therapies has not been established,6 is discouraged unless the
patient is severely ill, and it will change management.
However, in such a case, that would not be elective.
Additionally, for stable patients with high likelihood of
having Group 2 and 3 PH, elective new patient evaluation
should be deferred until a later date due to the lack of estab-
lished therapies for these disease states at the moment. The
COVID-19 pandemic is an opportune time to use risk like-
lihood tools on who would benefit from undergoing a
RHC,7 and perhaps patients without RHF or those at
lower risk of actually having PAH can have their RHC
(and treatment) deferred in the short run.
Another challenge to our usual PAH care during the
COVID-19 pandemic is the initiation of PAH therapies at
home. Typically, some PAH medications including rioci-
guat, selexipag, and prostacyclins have been up-titrated at
home with frequent nursing visits. With current restrictions
on travel and the practice of social distancing, there is less
availability for nurses to access homes and hospitals for
teaching and up-titrating of therapies. This can be handled
by PH practice nurses and telemedicine phone calls/visits.
New intravenous starts may need longer teaching in hospital
to assure safety and good clinical practice.
Management of CTEPH will likely be similar to PAH
during the COVID-19 pandemic, when surgical intervention
and Balloon Pulmonary Angioplasty is going to be less
immediately available. In this setting, coordinating and
communicating care with specialized centers will be import-




It is common for PAH clinics to see clinically-stable patients
every three to six months based on ERS/ESC 2015 guide-
lines.5 This is similar for patients with CTEPH also, unless
in decompensated RHF. This practice, although only con-
sensus based, was developed because of the fragile nature of
PAH patients and the lack of predictability for response to
treatment, and the ongoing risk for disease progression in
prevalent cases. Since patients can rapidly clinically deteri-
orate, PAH-specific risk scores advocate frequent follow-up
to allow for a formal risk assessment during this time period
as well. However, given the potential risk of acquiring
COVID-19 infection by coming to a healthcare setting,
patients with underlying chronic cardiopulmonary disease
are being advised against non-essential travel and to practice
social distancing. Thus, a risk/benefit analysis evaluating
the need for in-person versus remote clinic visits, as well
as the need for certain diagnostic tests, is in order in the
current healthcare environment.
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How should stable patients best be evaluated and moni-
tored during this pandemic? Many PAH programs have
already introduced telehealth programs in response to the
COVID-19 pandemic, where patients’ current health status
is evaluated by telephone or video conferencing. Although
there are limitations to telehealth, such as inability to do
comprehensive physical exams and essential diagnostic test-
ing, it is likely that many patients are capable of self-descrip-
tion of their PAH signs and symptoms and thus can guide
their management. Additional limitations to telehealth
include an inability to reliably measure vital signs, as well
as patient accessibility to access audio and/or video confer-
encing technology and familiarity with these technologies,
especially for patients with limited means. As telehealth
evolves, new questions about delivery of care will certainly
emerge which will need to be measured against doing what is
best for the overall safety and well-being of the patient.
Routine diagnostic testing
Similar to routine clinic visits, it is common for PAH
patients to undergo frequent echocardiograms, RHCs, six
minute walk tests, and laboratory tests which form an inte-
gral part of the monitoring and risk stratification tools
which many PAH providers use to guide therapeutic
options. With the COVID-19 pandemic, it is important to
consider the additive value of these sometimes comprehen-
sive tests in the context of the risks associated with visiting
the hospital or clinic to obtain them. While laboratory
values for N-terminal (NT)-pro hormone Brain natriuretic
peptide (NT-proBNP) and Brain natriuretic peptide (BNP)
are often used as a surrogate for RHF in patients with PAH,
there are risks for patients traveling to a laboratory to
obtain these tests. In patients who are on anticoagulation
for CTEPH, atrial fibrillation, pump infusion, or other rea-
sons, it may be worth considering transitioning to direct oral
anticoagulants or low-molecular-weight heparin to avoid
the laboratory visit necessary to obtain and monitor a thera-
peutic International Normalised Ratio (INR) with warfarin
use. Similar to procedures which will be limited during this
time, such as echocardiogram, it is worth reconsidering
whether any of the tests performed for routine follow-up
change clinical management sufficiently to warrant the risk
of getting the test performed.
Unstable patients
The focus of this manuscript is on the general management
of COVID-19 infection in PAH, as opposed to the other
etiologies responsible for decompensation of PAH, which
have been addressed elsewhere.8
The incubation period for COVID-19 is estimated to be
four days (interquartile range: 2–7 days). Frequently-
reported symptoms of patients admitted to the hospital
with COVID-19 infection include fever, cough, myalgia,
fatigue, and shortness of breath (3–31%) at illness
onset.9–11 Most patients who are hospitalized with con-
firmed COVID-19 are diagnosed with pneumonia.9–11
Patients with comorbidities have an increased mortality,
>10% for those with cardiovascular disease, 7% for
Diabetes Mellitus Type 2, and 6% for systemic hypertension,
chronic respiratory disease, or cancer.12 In one study, patients
who developed respiratory failure, septic shock, or multiple
organ dysfunction had a 49% mortality.12 Approximately
20–30% of patients hospitalized with COVID-19 and pneu-
monia have required respiratory support in intensive care
units (ICUs).9,11 Among those admitted to ICUs, to a varying
extent, patients have required high-flow oxygen therapy,
mechanical ventilation (Bilevel Positive Airway Pressure
[BiPAP]/continuous positive airway pressure [CPAP]), intub-
ation, and in some cases ECMO. The unique transmission
risks associated with this viral infection dissuade use of less
intensive ventilatory support in lieu of early intubation, which
is something we otherwise try to avoid in patients with PAH.
There are no currently approved specific treatments for
COVID-19.13 Remdesivir is an investigational antiviral drug
that has been shown to have in-vitro activity against
COVID-19.14 It has been made available for compassionate
use in the US during the COVID-19 pandemic. There is no
known interaction of remdesivir with PAH therapies.
Additionally, there is some interest in investigating short-
term use of hydroxychloroquine, chloroquine, and azithro-
mycin in patients with COVID-19 infection.
In patients with PAH experiencing worsening RHF, the
differential diagnosis includes sepsis, ischemia, progression
of disease, or COVID-19 infection (or a combination of
these factors). During the current pandemic, fever at home
in a PAH patient should be assumed to represent a COVID-
19 infection. If a patient is having worsening respiratory
symptoms requiring hospitalization, they should be evalu-
ated and tested for COVID-19. Data available suggests that
in Italy, there are not large numbers of patients with PAH
who show right ventricle (RV) decompensation during and
after mild COVID-19 infection. The same experience seems
to be that in the US so far (personal communication).
However, based on prior publications evaluating the effects
of acute RHF superimposed on systemic infection,15–18 it is
likely that RHF and concomitant COVID-19 infection will
lead to increased mortality in the PAH patient.
In our experience so far, hypoxia and systemic inflamma-
tory response syndrome with PAH and COVID-19 infection
is difficult to treat. There are data on the risk of ARDS in
pulmonary vascular disease suggesting that COVID-19
pneumonia in the context of PAH will more commonly
result in ARDS.19,20 In this setting, management of ventila-
tion presents unique challenges. BiPAP/CPAP is difficult
due to the physiology of RHF8 and due to the aerosolization
of virus, so high flow nasal cannula is preferred. Intubation
can be fatal in PAH if performed and managed improp-
erly.8,16 Plus extubation post-treatment in the PAH patient
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with baseline cardiopulmonary disease is difficult. Systemic
blood pressure should be maintained with systemic vaso-
pressors, although the preferred agent is not well-defined.21
Despite a high likelihood for COVID-19, in a febrile PAH
patient, consideration should be given to start empiric,
broad-spectrum antibiotics at the onset of fever and worsen-
ing respiratory symptoms due to the risk of bacterial infec-
tion or superinfection being a contributing factor.
In patients with shock related or unrelated to COVID-19,
the role and route of PAH-specific therapies should be dis-
cussed with a PH expert. In general, PAH-specific therapies
should be continued during hospitalization and patients
unable to tolerate oral or inhaled medications may need to
be transitioned from oral to intravenous medications to get
through severity of a COVID-19 infection.22 It is important
to consider nitric oxide (NO) during clinical decompensa-
tion in lieu of agents that have the potential to lower blood
pressure (for example, phosphodiesterase 5 inhibitors, gua-
nylate cyclase stimulators). We have experience of delivering
NO at home during this pandemic, although this is unlikely
to be readily available in the near-term.23
Although ECMO is used in some COVID-19 patients
with refractory hypoxemia, in the cases that we have seen
to date involving PAH, this modality is particularly challen-
ging and decisions about utilizing this resource-intensive
option during a pandemic have to be closely scrutinized,
especially in the absence of bridging to transplantation
during these difficult times.8,11,24 Society finds itself in an
unenviable position and increasingly will have to make dif-
ficult decisions about health care delivery and resource util-
ization, including the use of precious and intensive
interventions such as invasive ventilation and ECMO. In
particular, PAH patients will have great difficulty surviving
these types of interventions which poses a significant oppor-
tunity cost during a pandemic that is stretching the health
care system. It is anticipated that there will be shortages of
ventilators during the COVID-19 pandemic, which poses
even further concern for their utility in this population. As
a general recommendation, practitioners should consider
utilizing an established PAH-specific risk assessment tool
to help identify patients who are more likely to survive
heroic interventions during the COVID-19 outbreak.
Specifically, patients with a REVEAL 2.0 risk score  9
or those meeting at least 3 of 4 (invasive method) or at
least 2 of 3 (non-invasive method) LOW risk criteria per
the French Pulmonary Hypertension Registry risk tool,
have significantly better prognosis with their PAH and
make more suitable candidates for riskier acute interven-
tions during the COVID-19 crisis.25,26
Considerations for specialized PH centers
and regional PH programs
Specialized PH centers provide crucial service for the care of
PAH patients over broad areas.27,28 However, with travel
restrictions, it may be difficult for PAH patients to travel
to these centers. During the COVID-19 pandemic, these cen-
ters will likely need to increase their use of remote collabor-
ation with regional programs and community providers in
order to provide advice and suggestions regarding best prac-
tice. It will be important for specialty pharmacies that pro-
vide access to many PAH-specific therapies to work with
industry to ensure seamless distribution of therapies
during this crisis.
Regional PH programs27,28 provide important and easy-
access care to patients living with PAH. These programs will
become even more important during this crisis as they will
be the main resource for patients who are now discouraged
from traveling.
Implications for training PH providers and
implications for PH education programs
Educational programs such as preceptorships and symposia
will be more challenging (and slow to react) during this time
of uncertainty and new and innovative educational
approaches will be essential. As we emphasize the health
of the entire PH community and population at-large, con-
ferences will be limited in scope and it will be difficult for
providers in a community setting to travel to specialized
centers for training and exposure to complex cases. In add-
ition, even conferences within hospitals are going to be dif-
ficult to have in the traditional sense due to ordinances
limiting gatherings of 10 or more people. Limited travel
will preclude expert-level face-to-face conferences and there-
fore increased reliance on telehealth and remote conferences
will be needed.
Education of patients and their families
With the prevalence of social media, it is important for PAH
patients and families to have trusted sources for advice. It
will be important for scientific communities to provide
timely, reliable updates on best practice in PAH, acknowl-
edging that the situation changes rapidly. Such information
is being made available and regularly updated through the
PHA,29 and other organizations.30
Impact on research programs
During this time, most sponsors of clinical trials have lim-
ited or halted subject enrollment. Similarly, due to travel
constraints and government mandates, non-essential per-
sonnel have been instructed to stay at home in many parts
of the world. In this setting, the ability to make advances
in the care of PAH is limited by traditional methods, and
novel studies and analyses are needed to continue to
advance this field. This may involve computational science
or existing registry studies, as well as modeling the impact of
COVID-19 on PAH using existing databases. Trials to
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evaluate safety of agents should be halted, and trials that
involve immunosuppressive agents should be re-evaluated
for risk versus benefit during the COVID-19 pandemic.
Trials necessitating contact with the PH site, for example
internal pump refills, will need to arrange for this care per
site feasibility or consider switching to an external pump in
the interim. This would be done at the sites’ hospital center
with close supervision. Enrolling new patients into clinical
trials, irrespective of phase (1–4) at this time is difficult and
of uncertain benefit, especially when taking exposure risk
into account. For those already enrolled in phase 2 and 3
trials, study visits could be converted to telemedicine visits
when possible to limit the risks to participants.
Future directions
Transformative impact of COVID-19 on PAH care
Although as outlined above, the issues facing current prac-
tice patterns in PAH can be utilized to direct care going
forward and perhaps issues such as telehealth will become
a more established practice in PAH.
Summary
As our world adjusts to a different way of living and inter-
acting as a society not seen worldwide since the Spanish flu
of 1918, our medical community rushes to try and expand
our understanding of how best to care for unique popula-
tions within the environment of COVID-19. Specifically,
this document attempts to address the needs of PAH pro-
viders and their patients. As PAH patients have shown to
have worse outcomes with all-cause hospitalizations,31 pro-
actively working to decrease the risk of COVID-19 infection
while continuing to provide a high-level of PAH care is
essential. Adjusting how we provide that care with increased
telemedicine visits, decreased exposures to healthcare envir-
onments for patients, and timely medication adjustments
will assist in our continued need to provide for patients des-
pite the ever changing landscape.
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